Hui Liu

Hui Liu is the current Chief Technology Officer at Matinas BioPharma. Prior to this, they worked at Alcon, a Novartis company, from January 2015 to May 2017. At Alcon, they held various positions, including Sr Technical Lead, Associate Director, and CMC lead for nanoparticle gene therapy formulation and biomaterial. In these positions, they were responsible for developing drug delivery proposals, CMC strategies, road maps, milestones, and timelines. Hui also led teams to achieve the goals within timeline and budget. Her projects included topical formulations, intraocular drug delivery, and medical devices.

Liu has extensive experience in drug delivery, pharmaceutical development, and formulation. Hui is an expert in nanotechnology and has developed several groundbreaking innovations in the field of gene therapy. In addition to their work at Alcon, they have also been invited to keynote the 6th American Drug Delivery and Formulation Summit. Her key competencies include ophthalmology, design control, combination product development, medical device development, and polymer drug delivery platforms.

Hui Liu received their BS in polymer chemistry from the University of Science and Technology of China. Hui then went on to complete their Ph.D in polymer chemistry from the University of Michigan. Finally, they earned their Master of Business Administration (M.B.A.) from the University of Massachusetts, Amherst.

Hui Liu works with James J. Ferguson - Chief Medical Officer, Raphael J. Mannino - Chief Scientific Officer, and Keith A. Kucinski - CFO. Hui Liu reports to Jerome D. Jabbour, CEO.